Medron Medical Systems Inc. is Introducing MVision’s Groundbreaking Auto-Segmentation Solution to Canada

Helsinki – December 9, 2021 – MVision AI, the leading software service provider of guideline-based AI segmentation, GBAIS™, for radiotherapy treatment planning, declares a new distribution partnership with Medron Medical Systems, Canada’s choice health equipment provider (subject to approval from Health Canada).

The collaboration authorizes Medron Medical Systems to distribute products and services of MVision AI throughout Canada. Medron Medical Systems and MVision AI are devoted to helping oncology departments receive exceptional and consistent radiotherapy machine learning solutions across Canada. MVision AI’s specialists will be collaborating with Medron Medical System Inc.’s experts to undertake the distribution of the finest, most convenient, and consistent radiotherapy services. 

“Innovation and the introduction of new modalities in radiation oncology have changed the landscape in how radiation therapy is delivered. The introduction of artificial intelligence (AI) in treatment planning is the beginning of a new era that will ultimately lead to greater accuracy in radiation dose delivery, leading to improved patient outcomes,” said Ronald Wallace, President of Medron Medical Systems Inc. 

“Medron Medical Systems Inc. is proud to partner with MVision in developing the Canadian market of their Automatic Segmentation platform using their unique AI algorithms.”

As stated by MVision AI’s CEO and Co-Founder, Mahmudul Hasan, “MVision is continuing its rapid expansion. We are excited to start this partnership with Medron Medical Systems Inc. for Canadian hospitals. We are well ahead of our mission to serve radiotherapy patients with fast and high-quality treatment plans.” 

For additional inquiries on Medron Medical System:

Medron Medical System

Website: https://www.medron.ca/

Email: info@medron.ca

Tel: +1 613-769-3302 

MVision AI is active on LinkedInTwitterFacebook, and Instagram. Follow us on social media and subscribe to our newsletter to stay up-to-date on the latest MVision AI news.

Are you eager to learn more about GBAIS™? We welcome you to contact MVision AI:

c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.

Tel: +358 (0) 40 5489 229

Website: https://www.mvision.ai 

Email: info@ mvision.ai 

For media inquiries:

Tel: +358 40 500 7915

Email: pr@mvision.ai

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

2.2.2024

World Cancer Day – Joining efforts for a better cancer care

World cancer day, celebrated on the 4th of February, was established more than 20 years ago. It represents an initiative of the Union for International Cancer Control (UICC) , the oldest and largest global membership organization dedicated to taking action on cancer. UICC has over 1150 member organizations in 172…

News

30.1.2024

How can AI-based auto-contouring improve the life of patients who need palliative radiation therapy?

Cancer is one of the leading causes of morbidity and death, worldwide. Approximately 18 million people are diagnosed with cancer each year and the number is expected to increase. Pain is experienced by two thirds of patients having advanced, metastatic or terminal disease (1). Other symptoms caused by compression on…

Articles

22.1.2024

MVision AI Announces Partnership with Medron Medical Systems (Canada)

HELSINKI, Finland - January 22, 2024 MVision AI, a premier software service provider of GBS™ (Guideline-Based Segmentation) solution for same-day radiotherapy treatment planning, proudly announces a new distribution partnership with Medron Medical Systems, a leading health equipment provider in Canada. This collaboration follows the receipt of Medical Device License (MDL)…

Press Releases